Focus on the Use of Resveratrol in Bladder Cancer

11Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

Bladder cancer is the most common tumor of the urinary system, with a high incidence in the male population. Surgery and intravesical instillations can eradicate it, although recurrences are very common, with possible progression. For this reason, adjuvant therapy should be considered in all patients. Resveratrol displays a biphasic dose response both in vitro and in vivo (intravesical application) with an antiproliferative effect at high concentrations and antiangiogenic action in vivo (intraperitoneal application) at a low concentration, suggesting a potential role for it in clinical management as an adjuvant to conventional therapy. In this review, we examine the standard therapeutical approach to bladder cancer and the preclinical studies that have investigated resveratrol in xenotransplantation models of bladder cancer. Molecular signals are also discussed, with a particular focus on the STAT3 pathway and angiogenic growth factor modulation.

Cite

CITATION STYLE

APA

Zucchi, A., Claps, F., Pastore, A. L., Perotti, A., Biagini, A., Sallicandro, L., … Fioretti, B. (2023, March 1). Focus on the Use of Resveratrol in Bladder Cancer. International Journal of Molecular Sciences. Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/ijms24054562

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free